Lab Head

Research Group Home Page: 
Jodrell Group

In the Pharmacology & Drug Development Group we are taking novel drugs (small molecules and therapeutic antibodies) and drug combinations from in vitro assays through preclinical development and into Phase I clinical trials.  Focused particularly on pancreatic cancer, using innovative cell-based and preclinical models, aiming to reduce the failure rate of cancer drug trials. I lead a team, supervise students, and manage scientific projects. I have 25 years’ research experience in academic oncology genetics,  biology and pharmacology plus 6 years in commercial drug discovery and development. More than 70 publications, >6,000 citations; RG Score 40.73, h-index 37, i10 index 50.

Work address: 
Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE
Publications: 

Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.

E-pub date: 31 Dec 2018


The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.

E-pub date: 11 Jun 2018


Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

E-pub date: 01 Jun 2018


Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.

E-pub date: 31 Mar 2018


Development of In Vitro Co-Culture Model in Anti-Cancer Drug Development Cascade.

E-pub date: 31 Aug 2017


Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy.

E-pub date: 31 May 2017


A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level.

E-pub date: 15 Jan 2017


Combenefit: an interactive platform for the analysis and visualization of drug combinations.

E-pub date: 15 Sep 2016


Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.

E-pub date: 31 Jul 2016


Understanding the Complexity of Porous Graphitic Carbon (PGC) Chromatography: Modulation of Mobile-Stationary Phase Interactions Overcomes Loss of Retention and Reduces Variability.

E-pub date: 21 Jun 2016


An automated fitting procedure and software for dose-response curves with multiphasic features.

E-pub date: 01 Oct 2015


CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.

E-pub date: 01 Sep 2015


The EGFR demonstrates linear signal transmission.

E-pub date: 31 Aug 2014


Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.

E-pub date: 15 Jul 2014


SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.

E-pub date: 01 Jun 2014


Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes.

E-pub date: 21 Nov 2013


Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.

E-pub date: 31 Aug 2013


Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells.

E-pub date: 31 Oct 2012


Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.

E-pub date: 31 Aug 2012


A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.

E-pub date: 01 Nov 2011


Accumulation and metabolism of drugs and CYP probe substrates in zebrafish larvae.

E-pub date: 31 Aug 2010


Zebrafish based assays for the assessment of cardiac, visual and gut function–potential safety screens for early drug discovery.

E-pub date: 31 Jul 2008


Validation of the use of zebrafish larvae in visual safety assessment.

E-pub date: 31 Jul 2008


GBR12909 possesses anticonvulsant activity in zebrafish and rodent models of generalized epilepsy but cardiac ion channel effects limit its clinical utility.

E-pub date: 31 Aug 2007


Identification of novel VHL targets that are associated with the development of renal cell carcinoma.

E-pub date: 08 Mar 2007


Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands.

E-pub date: 28 Feb 2003


Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.

E-pub date: 01 Jul 2002


MET mutation and familial gastric cancer.

E-pub date: 31 Aug 2001


Germline mutation analysis of the transforming growth factor beta receptor type II (TGFBR2) and E-cadherin (CDH1) genes in early onset and familial colorectal cancer.

E-pub date: 01 Feb 2001


Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer.

E-pub date: 01 Apr 1999


Molecular genetic analysis of von Hippel-Lindau disease.

E-pub date: 01 Jun 1998


Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes.

E-pub date: 01 May 1998


Mapping the multiple self-healing squamous epithelioma (MSSE) gene and investigation of xeroderma pigmentosum group A (XPA) and PATCHED (PTCH) as candidate genes.

E-pub date: 01 Dec 1997


Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis.

E-pub date: 01 May 1996


Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.

E-pub date: 01 Apr 1996


Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene.

E-pub date: 01 Nov 1995


Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.

E-pub date: 01 Dec 1994


Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype.

E-pub date: 31 Aug 1994


Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene.

E-pub date: 01 Apr 1994


A PCR generated AccI RFLP in the 3′ untranslated region of the von Hippel-Lindau disease (VHL) tumour suppressor gene.

E-pub date: 01 Feb 1994


Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22.

E-pub date: 01 Feb 1994


Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours.

E-pub date: 01 Jan 1994


von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis.

E-pub date: 01 Dec 1993


TaqI and PstI RFLPs in the von Hippel-Lindau disease gene (VHL).

E-pub date: 01 Oct 1993


Mapping the Von Hippel-Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis.

E-pub date: 01 Jul 1993


Identification of the von Hippel-Lindau disease tumor suppressor gene.

E-pub date: 30 Apr 1993


Genetic linkage between von Hippel-Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus.

E-pub date: 01 Mar 1993


Detailed genetic mapping of the von Hippel-Lindau disease tumour suppressor gene.

E-pub date: 01 Feb 1993


Presymptomatic diagnosis of von Hippel-Lindau disease with flanking DNA markers.

E-pub date: 01 Dec 1992


Investigations of the relationship between cell proliferation and differentiation of HL-60 cells induced to differentiate by N-methylformamide.

E-pub date: 01 Aug 1988


Show all